|
Species | Antidepressant treatment | Experimental paradigm | Effect on neurogenesis | Effects on behavior | References |
|
129/SvEv
| Fluoxetine (SSRI): 10 mg/kg/day via drinking water for 28 days | Proliferation: BrdU (4 × 75 mg/kg, ip) at 2-hour intervals and analysis at 24 hours after last BrdU injection. Survival: BrdU (4 × 75 mg/kg, ip) at 2-hour intervals and analysis at 28 days after last BrdU injection. | Increased cell proliferation and neuronal maturation.
| Less depressive-like behavior in novelty suppressed feeding test. | [47] |
|
Sprague Dawley rat
| Fluoxetine (SSRI): 5 mg/kg (ip) 1, 5, 14, 28 d. Tranylcypromine: 7 × 7.5 mg/kg (ip) daily, then 14 × 10 mg/kg (ip) daily. Reboxetine: 20 mg/kg, 2x per day for 21 d | Proliferation: BrdU (4 × 75 mg/kg, ip) at 2-hour intervals, then 24-hour pulsing-chase. Survival: BrdU (4 × 75 mg/kg, ip) at 2-hour intervals, then 28-day pulsing chase. | Fluoxetine (SSRI): increased cell proliferation and neuronal maturation. Tranylcypromine: increased cell proliferation Reboxetine: increased cell proliferation. | NS | [38] |
|
129/SvEv | Fluoxetine (SSRI): 18 mg/kg daily by gavage for behavior test and via drinking water for all experiments for 5 days (subchronic) or 28 days (chronic). | Proliferation: BrdU (1 × 150 mg/kg, ip) at 2-hour pulsing chase. Dendritic maturation, survival, and neuronal maturation: BrdU (4 × 75 mg/kg, ip over 8 hours) on day 0, started fluoxetine treatment on day 1, and analysis on day 21 by BrdU and DCX coimmunostaining. | Increased cell proliferation in chronic treatment of fluoxetine. No change in number of DCX+ immature neurons. Increased dendritic length and dendritic complexity in chronic treatment of fluoxetine, but not subchronic treatment measured by BrdU+ DCX+ colabeled neurons. Increased survival rate and neuronal maturation in chronic treatment of fluoxetine. | Less depressive-like behavior by chronic fluoxetine treatment (but not subchronic) in novelty suppressed feeding test. | [48] |
|
Nestin-CFPnuc mouse | Fluoxetine (SSRI): 10 mg/kg (ip) daily for 15 days.
| Proliferation: BrdU (1 × 150 mg/kg, ip) and analysis 1 day later. Survival: BrdU (1 × 150 mg/kg, ip) and analysis 30 days later. | Increased proliferation of amplifying neural progenitors (ANPs), but no change in quiescent neural progenitors (QNPs). Increased survival rate. | NS | [49] |
|
Wistar rat | Escitalopram (SSRI): 5 mg/kg (ip) for 4 weeks. | BrdU (4 × 100 mg/kg, ip) with 2-hour interval during one day and analysis at 16 hours after the last BrdU injection. | Increased cell proliferation in chronic treatment of escitalopram under mild stress condition, but no change under the normal condition. | Chronic treatment of escitalopram shows recovery from anhedonic-like behavior caused by the mild stress condition. | [50] |
|
BALB/c mouse | Fluoxetine (SSRI): 10 mg/kg (ip) daily for 28 days, Imipramine (TCA): 20 mg/kg (ip) daily for 28 days. | BrdU (4 × 75 mg/kg, ip) with 2 hours interval and analysis at 24 hours after last BrdU injection.
| Increased cell proliferation in chronic treatment of fluoxetine and imipramine under unpredictable chronic mild stress. | Chronic treatment of fluoxetine and imipramine shows recovery from depressive-like behavior caused by unpredictable chronic mild stress condition. | [51] |
|
Wistar rat | Lithium chloride: 2.5 mEq/kg (ip) for 14 days. | BrdU (50 mg/kg, ip) daily during last 3 days of experimental period | Increased proliferation, neuronal maturation and glial maturation of neural progenitors under normal conditions. Lithium treatment shows recovery from neurogenesis deficits under unpredictable chronic mild stress condition. | Lithium treatment shows less depressive-like behavior under normal conditions. Lithium treatment shows recovery from depressive-like behavior caused by unpredictable chronic mild stress condition. | [52] |
|